Minor non-fermenting Gram-negative bacilli in Europe, 2020-2024 (MINOFEu) - PubMed
5 days ago
- #European microbiology
- #Non-fermenting Gram-negative bacilli
- #Antimicrobial resistance
- The study focuses on minor non-fermenting Gram-negative bacilli (NFGNB) in Europe from 2020-2024.
- A total of 4,420 minor NFGNB isolates were analyzed from blood cultures in 56 European hospitals.
- Stenotrophomonas maltophilia was the most prevalent species (52.4%), followed by Achromobacter xylosoxidans (7.8%), Sphingomonas paucimobilis (5.3%), and Burkholderia cepacia complex (4.8%).
- MALDI-TOF mass spectrometry was the primary tool for species identification (98%).
- Antimicrobial susceptibility testing was mostly conducted using broth microdilution (57%), disk diffusion (57%), and gradient diffusion MIC strip (54%) methods.
- S. maltophilia showed resistance to sulfamethoxazole/trimethoprim (11%) and potential resistance to cefiderocol (2%).
- A. xylosoxidans exhibited high resistance to meropenem (10%), piperacillin/tazobactam (24%), and sulfamethoxazole/trimethoprim (53%).
- S. paucimobilis demonstrated over 90% susceptibility to several antibiotics, including amoxicillin/clavulanate and meropenem.
- The study highlights the need for improved diagnostic and antimicrobial strategies for minor NFGNB in Europe.